Use access key #2 to skip to page content.
$23.12 -0.88 (-3.67%)
1/9/2009 4:00 PM

Alnylam Pharmaceuticals, Inc. (ALNY)

CAPS Rating:
***

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.

View All Commentary (ALNY)

Recs

1

Avatar daviddai (49.81) Submitted: 3/08/07 3:06 PM : Underperform Start Price: $17.96 ALNY Score: -65.38

The company is trading at 18/share. This price is overvalued for a 600M Market Cap company. 1. weak product pipeline. With the exception of 1 product, all other proudcts are at preclinical stage, which means that it'll take at least 3 years for them to take off. There's too much risk with the preclinical data. The leading candidate is clinical 1. Therefore, it'll still take some time for us to see what holds for the products and the stocks.

Report this Post Replies: 0 | Reply | Permalink

Featured Broker Partners

Sponsored Links